In contrast, the 1-, and 2-year rate of HCC development in patients with low/high risk of AFP at 1 year after SVR24 were 1.6%/1.6%, and 0.0%/2.9%, respectively and there was no significant difference between high and low-risk groups (p = 0.8, Figure 2B). This evidence concerns the gene AFP and hepatocellular carcinoma.